Suécia - sueco - Läkemedelsverket (Medical Products Agency)

2care4 aps - dalteparinnatrium - injektionsvätska, lösning i förfylld spruta - 18000 ie - dalteparinnatrium 18 kie aktiv substans

Suécia - sueco - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - dalteparinnatrium - injektionsvätska, lösning i förfylld spruta - 5000 ie - dalteparinnatrium 5 kie aktiv substans

Suécia - sueco - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - dalteparinnatrium - injektionsvätska, lösning i förfylld spruta - 7500 ie - dalteparinnatrium aktiv substans

União Europeia - sueco - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacciner - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. användning av detta vaccin bör ske i enlighet med officiella rekommendationer.

União Europeia - sueco - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatid - osteoporosis; osteoporosis, postmenopausal - calciumhomeostas - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

União Europeia - sueco - EMA (European Medicines Agency)

incline therapeutics europe ltd - fentanylhydroklorid - smärta, postoperativ - smärtstillande medel - ionsys är indicerat för hantering av akut måttlig till svår postoperativ smärta hos vuxna patienter.

Suécia - sueco - Läkemedelsverket (Medical Products Agency)

teva sweden ab - teriparatid (syntetisk) - injektionsvätska, lösning i förfylld injektionspenna - 20 mikrogram/80 mikroliter - mannitol hjälpämne; teriparatid (syntetisk) 0,25 mg aktiv substans

Suécia - sueco - Läkemedelsverket (Medical Products Agency)

medical developments ned b.v. - metoxifluran - inhalationsånga, vätska - 99,9%, 3 ml - butylhydroxitoluen hjälpämne; metoxifluran 1,42 g aktiv substans

Suécia - sueco - Läkemedelsverket (Medical Products Agency)

2care4 aps - teriparatid (syntetisk) - injektionsvätska, lösning i förfylld injektionspenna - 20 mikrogram/80 mikroliter - teriparatid (syntetisk) 0,25 mg aktiv substans; mannitol hjälpämne

Suécia - sueco - Läkemedelsverket (Medical Products Agency)

teva pharma bv - fentanylcitrat - komprimerad sugtablett - 1200 mikrogram - fentanylcitrat 1885,2 mikrog aktiv substans; glukosmonohydrat hjälpämne; sackaros hjälpämne; propylenglykol hjälpämne - fentanyl